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Abstract
The formin family proteins play pivotal roles in actin filament assembly via the FH2 domain. The mammalian formin Fhod3 is
highly expressed in the heart, and its mRNA in the adult heart contains exons 11, 12, and 25, which are absent from non-
muscle Fhod3 isoforms. In cultured neonatal cardiomyocytes, Fhod3 localizes to the middle of the sarcomere and appears
to function in its organization, although it is suggested that Fhod3 localizes differently in the adult heart. Here we show,
using immunohistochemical analysis with three different antibodies, each recognizing distinct regions of Fhod3, that Fhod3
localizes as two closely spaced bands in middle of the sarcomere in both embryonic and adult hearts. The bands are
adjacent to the M-line that crosslinks thick myosin filaments at the center of a sarcomere but distant from the Z-line that
forms the boundary of the sarcomere, which localization is the same as that observed in cultured cardiomyocytes. Detailed
immunohistochemical and immuno-electron microscopic analyses reveal that Fhod3 localizes not at the pointed ends of
thin actin filaments but to a more peripheral zone, where thin filaments overlap with thick myosin filaments. We also
demonstrate that the embryonic heart of mice specifically expresses the Fhod3 mRNA isoform harboring the three
alternative exons, and that the characteristic localization of Fhod3 in the sarcomere does not require a region encoded by
exon 25, in contrast to an essential role of exons 11 and 12. Furthermore, the exon 25-encoded region appears to be
dispensable for actin-organizing activities both in vivo and in vitro, albeit it is inserted in the catalytic FH2 domain.
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Introduction
The sarcomere, the contractile unit of striated muscle, occurs
from a direct result of the precise alignment and organized
integration of actin-based thin filaments and myosin-based thick
filaments [1]. The actin thin filaments, having a uniform length,
are tethered at the barbed ends by sarcomeric a-actinin to the Z-
line, which forms the boundary of the sarcomere. The pointed
ends of the actin filaments are capped with tropomodulin (Tmod),
and slide into a lattice of thick myosin filaments that are
corsslinked at the M-line in the center of the sarcomere; a zone
containing myosin filaments is known as A-band. The highly
ordered array of thin actin filaments is not static as previously
thought, but dynamically organized during both assembly and
maintenance of the sarcomere [2–4], although the precise
mechanism for organization and turnover of actin filaments in
the sarcomere is still unclear [5]. Several actin-associating proteins
have recently been proposed as key regulator of actin dynamics
during sarcomere organization, for example, the Tmod-related
protein leiomodin in cardiomyocytes [6] and the giant actin-
binding protein nebulin in the skeletal muscle [7]. Fhod3, a
member of formin family proteins that regulate actin filament
assembly via the formin homology 2 (FH2) domain [8,9], is
another probable candidate for a key regulator: depletion of
Fhod3 in cultured cardiomyocytes disrupts sarcomere organization
[10].
The mouse FHOD3 gene consists of 28 exons (see Figure 1A). As
we have previously shown [11], exons 11 and 12 exist in the
mRNA expressed in the heart, but are simultaneously spliced out
in the kidney and brain. Iskratsch et al. have recently reported that
the Fhod3 mRNA in the adult heart and skeletal muscle also
contains another exon, i.e., exon 25 [12]; this striated muscle-
specific exon encodes the acidic-residue-rich sequence of eight
amino acids, T(D/E)5XE, that is inserted at the position close to
the C-terminal end of the FH2 domain. It has remained unclear
whether these alternative exons occur during development of the
heart.
Using rat neonatal cardiomyocytes in culture, we have
previously shown that Fhod3 protein localizes in the middle of
the sarcomere as two bands separated by the M-line: they are
more adjacent to the M-line than to the Z-line [10]. The
characteristic localization of Fhod3 within the sarcomere has
recently been confirmed using the same cells [12]. The N-terminal
region, which is encoded by exons 11 and 12, appears to play a
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lacking this region fails to localize to the sarcomere when
ectopically expressed in cultured cardiomyocytes [10]. On the
other hand, it is still possible that Fhod3 localization in cultured
cardiomyocytes may not reflect in situ localization, since the
sarcomere in freshly isolated cardiomyocytes once disassembles
and then reassembles or newly assembles during culture in vitro
[4,13]. Iskratsch et al. has recently proposed that, in the adult
heart, Fhod3 mainly localizes to the Z-line but not to the middle
region of the sarcomere, in contrast to its localization in cultured
cardiomyocytes [12].
Here we show that, in sections prepared from embryonic and
adult hearts of mice as well as those from an adult human heart,
three independent antibodies against Fhod3 all exist as two bands
in the middle of the sarcomere in the same manner as in cultured
cardiomyocytes. Detailed immunohistochemical studies by co-
staining with antibodies against Tmod and immuno-electron
microscopic analysis reveal that Fhod3 localizes not at the pointed
ends of thin actin filaments but to a more peripheral zone, where
thin filaments overlap with thick myosin filaments. We also
demonstrate that the Fhod3 mRNA isoform in the heart of mice
embryos also contains the alternative exons 11, 12, and 25, and
that the characteristic sarcomere localization of Fhod3 is
independent of the T(D/E)5XE region encoded by exon 25, in
contrast to an essential role of exons 11 and 12. Furthermore, the
exon 25-encoded region appears to play a dispensable role in
actin-assembling activities despite of its localization within the
catalytic FH2 domain.
Results
Expression of Fhod3 isoforms in embryonic mice
To investigate the Fhod3 isoform expressed in the embryonic
heart, we first tested whether exon 25 is present in Fhod3 mRNAs
by RT-PCR analysis with specific primers (Figures 1B and 1C)
using total RNA obtained from various tissues of mouse embryos
at embryonic day 17.5 (E17.5) (Figure 1D); the presence of exon
25 was confirmed by sequence analysis of RT-PCR products
subcloned (Table 1). Fhod3 mRNAs containing exon 25 were
expressed highly in the heart and slightly in the skeletal muscle,
while exon 25 was absent from the Fhod3 mRNAs in the brain
and kidney (Figure 1D).
We next investigated the alternative splicing of exons 11 and 12
in Fhod3 mRNAs by RT-PCR with two primers that flank exons
11–12 (Figure 1B) using total RNA from mouse embryonic tissues.
As shown in Figure 1E, exons 11 and 12 were spliced out from the
Fhod3 mRNAs in the brain and kidney, whereas these two exons
were retained in the cardiac isoform. A similar tissue-specific
Figure 1. Expression of Fhod3 isoforms in the embryonic tissues. (A) Exon structure of the moue Fhod3 gene. Alternative splicing exons are
indicated by gray boxes. (B) Schematic presentation of domain structure of mouse Fhod3. The alternative splicing regions are in black boxes, and
primers for RT-PCR analysis are indicated by arrows. (C) Specific primers designed for isoforms derived from the alternative splicing in the C-terminal
FH2 domain. The primers ‘S6’ and ‘S7’ are specific for Fhod3 mRNAs with and without exon 25 that encodes the T(D/E)5XE region (boxed in black),
respectively. The primer ‘S8’ is common for both variants. (D) Tissue-specific expression of the ‘‘T(D/E)5XE’’ exon in mouse embryos. The RT-PCR
products using specific primers (shown in B and C) were subjected to agarose-gel electrophoresis. sk. muscle, skeletal muscle. (E) Tissue-specific
expression of splicing variants lacking exons 11 and 12. The RT-PCR products (shown in B) were subjected to agarose-gel electrophoresis.
doi:10.1371/journal.pone.0034765.g001
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[11,12]. Taken together, the embryonic heart as well as the adult
one appears to express almost exclusively the Fhod3 mRNA
isoform containing all the three alternative exons 11, 12, and 25.
Localization of Fhod3 in the embryonic heart
To investigate Fhod3 localization in the embryonic heart, we
first performed immunofluorescence staining with the anti-Fhod3-
(650–802) antibodies using cultured cardiomyocytes that were
isolated from the mouse embryonic heart. As shown in Figures 2A
and B, Fhod3 localized as two closely spaced bands in the
sarcomere, which was bordered by the Z-lines marked with the
anti a-actinin antibody. The manner of Fhod3 localization in
embryonic mouse cardiomyocytes is the same as that observed in
rat neonatal cardiomyocytes [10]. The characteristic localization
of Fhod3 in the sarcomere was also observed in frozen sections of
mouse embryonic hearts, when stained with the anti-Fhod3-(C-20)
antibodies (Figure 2C). Essentially the same results were obtained
by staining with two different anti-Fhod3 antibodies, i.e., the anti-
Fhod3-(650–802) and anti-Fhod3-(873–974) antibodies. Thus
Fhod3 appears to predominantly localize in situ as double bands
in the sarcomere of the mouse embryonic heart.
Localization of Fhod3 in the adult heart
To investigate in situ localization of Fhod3 in the sarcomere of
the adult heart, we immunostained glycerin-treated fibers from the
adult mouse heart with the anti-Fhod3-(650–802) antibodies
(Figure 3A). Signals by the antibodies, albeit not very intense,
indicated that Fhod3 localizes in the sarcomere in glycerinated
muscle fibers. We also examined Fhod3 localization in frozen
sections from the adult mouse heart. As shown in Figure 3B, the
anti-Fhod3-(650–802) and anti-Fhod3-(873–974) antibodies local-
ized as doublet in the sarcomere in the cryo-sections from adult
hearts. The localization of Fhod3 is essentially the same as that in
the embryonic heart (Figure 2). Although a substantial proportion
of the anti-Fhod3-(C-20) antibodies localizes to the Z-line (Figure
S1), signals on the Z-line were selectively attenuated by treatment
of these antibodies with an acetone powder of mouse embryonic
fibroblasts derived from Fhod3 knockout mice (manuscript in
preparation), as shown in Figure 3B (bottom panels). This
observation suggests that untreated anti-Fhod3-(C-20) antibodies
may contain in part those cross-reacting with a component of the
Z-line. Taken together, we conclude that Fhod3 mainly localizes
to the middle of the sarcomere not to the Z-line in the adult mouse
heart. This appears to be different from a recent observation that a
majority of Fhod3 is present at the Z-line in the adult mouse heart
[12].
In addition, to examine Fhod3 localization in the human adult
heart using the anti-Fhod3-(650–802) antibodies, we prepared
frozen sections from a piece of tissue in a noncardiomyopathic left
ventricle, which was obtained from a patient with severe aortic
stenosis at the time of therapeutic surgery. In the section, Fhod3
localized as doublet in the sarcomere, the boundaries of which
were formed by the Z-lines marked with the anti a-actinin
antibody (Figure 3C). Thus Fhod3 in the adult human heart likely
localizes in the sarcomere in a manner similar to that in the mouse
heart. Furthermore, we also tested Fhod3 localization in human
hearts with idiopathic dilated cardiomyopathy or idiopathic
hypertrophic cardiomyopathy. As shown in Figure 3D, the basic
pattern of sarcomere localization of Fhod3 was maintained in
these cardiomyopathic hearts.
Role of the T(D/E)5XE region in Fhod3 localization
When the Fhod3 mRNA containing all the exons except the
T(D/E)5XE-region-encoding exon 25 is ectopically expressed in
cultured cardiomyocytes from neonatal rats, its encoded protein
localizes in the sarcomere in the same manner as endogenous
cardiac Fhod3, which harbors the acidic region [10], indicating
that the T(D/E)5XE region is dispensable for Fhod3 localization.
On the other hands, it has been reported that, when ectopically
expressed in neonatal rat cardiomyocytes, a major population of
T(D/E)5XE-deficient Fhod3 forms aggregates in the cytoplasm;
however, the remainder appears to exist in the middle of the
sarcomere, as does the endogenous cardiac isoform [12]. To
clarify the role of the T(D/E)5XE region in Fhod3 localization in
situ, we generated transgenic mice that specifically express T(D/
E)5XE-deficient Fhod3 protein in the heart under the control of
the a-myosin heavy chain promoter (Figure S2). Immunohisto-
chemical analysis with the three different anti-Fhod3 antibodies
revealed that exogenously expressed T(D/E)5XE-deficient Fhod3
localizes as two closely spaced bands in the middle of the
sarcomere of the adult heart (Figure 4A). This localization is
essentially the same as the in situ localization of the T(D/E)5XE-
containing endogenous cardiac Fhod3 (Fig. 3), indicating that the
T(D/E)5XE region is dispensable for in situ localization of Fhod3
in the sarcomere.
The paired bands stained with the anti-Fhod3 antibodies were
well separated from the Z-line, marked with sarcomeric a-actinin
(Figure 4A), whereas they were adjacent to the M-line, indicated
by the presence of myomesin (Figure 4B). Although Fhod3
localized near the region where the pointed-end-capping protein
Tmod existed (Figure 4C), the paired bands of Tmod are closer to
each other (i.e., more distant from the Z-line) than those with those
of Fhod3, which is indicated by line scan graphs of fluorescence
intensity along the long axis of a sarcomere (Figure 4D): the
distances from the Z-line marker a-actinin to Fhod3
(0.8160.10 mm) were significantly shorter than those to Tmod
(0.9660.09 mm) (Figure 4E). Furthermore, co-immunostaining
with the anti-Fhod3 and anti-Tmod antibodies confirmed that
Fhod3 does not colocalize with the pointed-end capping protein
Table 1. Expression of alternatively spliced variants of Fhod3.
Heart Skeletal muscle Brain Kidney
Variant type Adult Embryo Adult Embryo Adult Embryo Adult Embryo
T(D/E)5XE (2) 0 (0) 1 (10) 0 (0) 1 (8) N.D.* 10 (100) N.D. 15 (100)
T(D/E)5XE (+) 10 (100) 9 (90) 10 (100) 11 (92) N.D. 0 (0) N.D. 0 (0)
The RT-PCR fragments amplified using specific primers flanking exon 25 (see Figure 1B) are subcloned and subjected to sequencing analysis. The number in parenthesis
indicates the percentage of each variant in the indicated tissue.
*N.D. not determined.
doi:10.1371/journal.pone.0034765.t001
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to the pointed-ends of thin actin filaments but rather to the zone
where actin filaments overlap with myosin filaments.
Furthermore, using sections of the heart prepared from Fhod3
transgenic mice, we examined the ultrastructural localization of
Fhod3 in the sarcomere by immuno-electron microscopic analysis.
As shown in Figure 4G, gold particles complexed with the anti-
Fhod3-(650–802) antibodies were accumulated on the myosin-
filament-containing A-band in the middle of the sarcomere. The
finding supports the idea that Fhod3 localizes to the zone where
actin filaments overlap with myosin filaments.
Role of the T(D/E)5XE region in Fhod3-induced actin
organization both in vivo and in vitro
To investigate the functional role of the T(D/E)5X region in the
FH2 domain, we compared the ability of Fhod3 to assemble actin
between Fhod3 proteins with and without the T(D/E)5XE region.
It is known that an N-terminally truncated Fhod3 (Fhod3-DN),
functioning as a constitutively active form, induces formation of
actin stress fibers when expressed in HeLa cells [10]. As shown in
Figure 5A, the N-terminally-truncated cardiac Fhod3, which
retained the T(D/E)5XE region, was as effective as the T(D/
E)5XE-deleted Fhod3-DN in stress fiber formation in HeLa cells,
indicating a dispensable role of this region in an in vivo actin
assembly activity. This is in good agreement with a recent result
obtained by quantitative estimation of cellular F-actin content that
the T(D/E)5XE region has no effect on the general ability of
Fhod3 to affect actin polymerization in cells [12]. Furthermore, we
tested an in vitro ability to assemble actin using purified Fhod3
proteins (Figure 5B). In an in vitro actin polymerization assay,
Fhod3-DN lacking the T(D/E)5XE region suppressed spontaneous
assembly of actin (Figure 5C), as shown in the previous study [10].
Under the conditions, Fhod3-DN including the T(D/E)5XE region
exerted almost the same effect (Figure 5C). On the other hand,
irrespective of the presence or absence of the T(D/E)5XE region,
Fhod3-DN carrying the I1127A substitution, defective in the actin-
binding activity [10], did not induce stress fiber formation
(Figure 5A). The substitution also resulted in a loss of the in vitro
actin-organizing activity (Figure 5C). Thus the T(D/E)5XE region
in the FH2 domain does not appear to be required for actin-
organizing activities both in vivo and in vitro.
Discussion
In the present study, we show that cardiac Fhod3, containing
the regions encoded by the three alternative exons 11, 12, and 25,
mainly localizes in situ as two closely spaced bands in the middle of
the sarcomere in both the developing embryonic heart and the
mature adult heart. The bands of Fhod3 exist not on the Z-line but
rather adjacent to M-line (Figures 2, 3, 4). Detailed immunohis-
tochemical analysis, in combination with immuno-electron
microscopic analysis, demonstrates that, in the sarcomere, Fhod3
localizes not at the pointed ends of thin actin filaments but to a
more peripheral zone, where thin filaments overlap with thick
myosin filaments (Figure 4). The characteristic localization of
Fhod3 in the sarcomere does not appears to require the T(D/
E)5XE region encoded by exon 25, in contrast to an essential role
of exons 11 and 12. The acidic region is also likely dispensable for
actin-organizing activities both in vivo and in vitro albeit it is inserted
in the catalytic FH2 domain (Figure 5).
In contrast to the present study, Iskratsch et al. have reported
that Fhod3 localizes mainly to the Z-line as well as the
intercalated-disc in the adult heart [12]. Although the reason for
the discrepancy is presently unknown, it might be explicable by the
difference in anti-Fhod3 antibodies used. They stained cardiac
Fhod3 with affinity-purified polyclonal antibodies raised against
the N-terminal region of Fhod3 (amino acid residues 1–339) [12].
On the other hand, we have used three distinct affinity-purified
polyclonal antibodies (the anti-Fhod3-(650–802), anti-Fhod3-
(873–974), and anti-Fhod3-(C-20) antibodies) raised against their
respective regions of amino acid residues 650–802, 873–974, and
1,567–1,586. In some cases, the affinity-purified anti-Fhod3-(C-20)
antibodies has been further treated with an acetone powder
prepared from Fhod3-deficient cells for complete removal of
crossly-reacting antibodies from the monospecific antibody
preparation, which treatment appears to emphasize that Fhod3
Figure 2. Localization of Fhod3 in the embryonic heart. (A)
Embryonic mouse cardiomyocytes were subjected to immunofluores-
cent double staining for endogenous Fhod3 (green) and a-actinin (red).
For Fhod3 staining, the anti-Fhod3-(650–802) polyclonal antibodies
were used. Bar, 5 mm. (B) Magnified image of single myofibril from
immunostained embryonic mouse cardiomyocytes. (C) Sections of
mouse embryonic hearts were subjected to immunofluorescent double
staining for endogenous Fhod3 (red) and a-actinin (green). For Fhod3
staining, the anti-Fhod3-(C-20) (top panels), the anti-Fhod3-(650–802)
(middle panels), and the anti-Fhod3-(873–974) (bottom panels)
polyclonal antibodies were used. Bar, 2 mm.
doi:10.1371/journal.pone.0034765.g002
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thin actin filaments overlap with myosin filaments in the
sarcomere of the adult heart. The discrepancy between the two
studies also might be due to the difference in fixation procedures:
Iskratsch et al. fixed cryosections by immersion with precooled
acetone [12], whereas we prepared tissue sections by a perfusion
fixation method with 3.7% formaldehyde to preserve the
ultrastructure of sarcomeres. In addition, it might be possible that
localization of Fhod3 alters depending on the stage of the
sarcomere, as does that of the Drosophila protein SALS in larval
somatic body wall muscles and adult indirect flight muscles: SALS
likely localizes at the pointed ends of thin filaments while they are
elongating, but it disappears from the pointed ends of full-growth
thin filaments and relocates at the region flanking the Z-line [14].
No evidence that Fhod3 localization alters in the heart has been
obtained so far, although our present study did not investigate the
Fhod3 localization during the elongating stage of the sarcomere.
The exon 25-encoded T(D/E)5XE region is not required for the
characteristic sarcomere localization of Fhod3 not only in cultured
cardiomyocytes but also in the heart of Fhod3 transgenic mice, as
shown here. On the other hand, it has been reported that, using
neonatal rat cardiomyocytes, a major population of ectopically-
expressed T(D/E)5XE-deficient Fhod3 forms aggregates in the
cytoplasm, although the remainder of this exogenous protein
seemingly exists in the middle of the sarcomere as does the
endogenous cardiac isoform [12]. It might be possible that,
compared with the T(D/E)5XE-containing Fhod3, the T(D/
E)5XE-deficient isoform is unstable but inaccessible to a usual
protein degradation pathway, and thus forms cytoplasmic
aggregates especially when expressed ectopically at a higher level.
The threonine residue of the T(D/E)5XE region has been shown
to be phosphorylated by casein kinase 2; the phosphorylation likely
prevents formation of aggregates, which are recruited to
autophagosomes [12].
In the sarcomere of the heart, Fhod3 localizes to neither end of
thin actin filaments but to the region where actin filaments overlap
with thick myosin filaments. On the other hand, Fhod3 likely
organizes F-actin assembly via the FH2 domain by associating
with the barbed end, in a manner similar to that by other formin
family proteins [10]. The functional link with the characteristic
localization of Fhod3 in the sarcomere is presently unknown,
which should be clarified in future studies.
Materials and Methods
Ethics Statement
Procedures using human samples were conducted in accordance
with the Declaration of Helsinki and approved by the Kyushu
University Institutional Review Board for Clinical Research
(Permit Number: 22-170). We obtained written informed consent
from all the participants. All procedures using mice were
performed in strict accordance with the guidelines for Proper
Conduct of Animal Experiments (Science Council of Japan). The
experimental protocol was approved by the Animal Care and Use
Committee of Kyushu University (Permit Number: A22-005-1).
All efforts were made to minimize the number of animals used and
their suffering.
Plasmids
The cDNA fragments encoding mouse Fhod3 of 1,578 amino
acids (designated as Fhos2L in [11]), which contains all the 28
exons except exon 25, was prepared as previously described [11].
The cDNA fragments encoding mouse Fhod3 of 1,586 amino
acids, which contains all the 28 exons, was cloned by RT (reverse
transcriptase)-polymerase chain reaction (PCR). The cDNAs for
Fhod3-DN, lacking the N-terminal 930 amino acids, were
constructed by PCR using the cDNAs encoding mouse Fhod3
with or without exon 25. The cDNA for mDia1-FH1FH2 (549–
1,175) was prepared as described previously [10]. Mutations
leading to the indicated amino acid substitutions were introduced
by PCR-mediated sited-directed mutagenesis. The DNA frag-
ments were ligated to pEGFP-C1 (Clontech) or pEF-BOS for
expression in HeLa cells as an N-terminally green fluorescent
protein (GFP)–tagged protein or for expression in HEK-293F cells
as an N-terminally FLAG–tagged protein, respectively. All the
constructs were sequenced for confirmation of their identities.
Antibodies
Rabbit polyclonal antibodies specific for Fhod3 (anti-Fhod3-
(650–802), anti-Fhod3-(873–974), and anti-Fhod3-(C-20) antibod-
ies) were prepared as previously described [11]. Briefly, the anti-
Fhod3-(650–802) and anti-Fhod3-(873–974) antibodies were
raised against the respective GST–fusion proteins comprising
amino acid residues 650–802 and 873–974 of Fhod3; the anti-
Fhod3-(C-20), was raised against a synthetic peptide correspond-
ing to the C-terminal 20 amino acids (1,567–1,586) of Fhod3.
These anti-Fhod3 antibodies were affinity purified by a HiTrap-
NHS column (Amersham Bioscience) conjugated with MBP–
fusion proteins corresponding to the immunizing regions or with
the synthetic peptide used for immunization, respectively. In the
case of staining of sections from hearts of adult mice, anti-Fhod3-
(C-20) antibodies were pre-adsorbed with an acetone powder of
mouse embryonic fibroblasts derived from Fhod3 knockout mice
(Acc. No. CDB0598K: http://www.cdb.riken.jp/arg/
mutant%20mice%20list.html). The details of the Fhod3 knockout
mice will be reported elsewhere. Immunofluorescent images using
unadsorbed anti-Fhod3-(C-20) antibodies without pre-adsorption
are shown in Figure S1. The specificity of the anti-Fhod3-(650–
802) antibodies was confirmed by immunoblot analysis using
cardiac tissue lysates (5 mg of protein) from Fhod3 knockout mouse
embryos at E10.5 or from heterozygous Fhod3
+/2 mouse embryos
at E10.5 (Figure S3). The mouse monoclonal antibody against a-
actinin (clone EA-53) was purchased from Sigma-Aldrich; the goat
polyclonal antibodies against myomesin-1 (C-16) from Santa Cruz;
Figure 3. Localization of Fhod3 in the adult heart. (A) Glycerinated fibers from adult mouse hearts were subjected to immunofluorescent
double staining for endogenous Fhod3 (red) and a-actinin (green). For Fhod3 staining, the anti-Fhod3-(650–802) polyclonal antibodies were used.
Bar, 5 mm. (B) Sections of adult mouse hearts were subjected to immunofluorescent double staining for endogenous Fhod3 (red) and a-actinin
(green) followed by phalloidin staining (not shown in merge). For Fhod3 staining, the anti-Fhod3-(650–802), the anti-Fhod3-(873–974), and the anti-
Fhod3-(C-20) polyclonal antibodies were used. The anti-Fhod3-(C-20) antibodies used here were pre-adsorbed with an acetone powder of mouse
embryonic fibroblast derived from Fhod3 knockout mice. For details, see ‘‘Materials and Methods’’. Bar, 2 mm. (C) Sections of tissues from a left
ventricle of a human heart were subjected to immunofluorescent double staining for endogenous Fhod3 (red) and a-actinin (green). For Fhod3
staining, the anti-Fhod3-(650–802) polyclonal antibodies were used. Bar, 2 mm. (D) Sections of tissues from a left ventricle of two patients (#1 and
#2) with idiopathic dilated cardiomyopathy (DCM) and a patients with idiopathic hypertrophic cardiomyopathy (HCM) were subjected to
immunofluorescent double staining for endogenous Fhod3 (red) and a-actinin (green). For Fhod3 staining, the anti-Fhod3-(650–802) polyclonal
antibodies were used. Bar, 2 mm.
doi:10.1371/journal.pone.0034765.g003
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Group; the mouse polyclonal antibodies against Tmod1 from
Abnova; the fluorescent secondary antibody conjugated with
Alexa Fluor 488 or 594 against mouse IgG, rabbit IgG, or goat
IgG from Invitrogen; and Alexa Fluor 555-conjugated F(ab’)2
fragment of anti-rabbit IgG from Cell Signaling Technology.
RT-PCR analysis
The expression of the Fhod3 mRNAs was determined by RT-
PCR using total RNA as a template, which was extracted from the
adult (3 weeks old) or embryonic (E17.5) C57BL/6 mice tissues
using TRIzol reagent (Invitrogen). Primers were designed on the
basis of the mouse sequence reported [11,12]. For detection of
exon 25, the following primers were used: ‘S6’, 59- GGGAA-
GATGATCACTGACTCT-39 (a forward primer specific for
Fhod3 mRNAs lacking exon 25); ‘S7’, 59- GACGAGGAT-
GAAGCTGAGTCT-39 (a forward primer specific for Fhod3
mRNAs containing exon 25); ‘S8’, 59- AGAGGGAAGATGAT-
CACTGAC-39 (a common forward primer for both isoforms); and
‘RV3’, 59-ATCAGTGACACTAGGTGACTC-39 (a common
reverse primer for both isoforms). The PCR fragments were
subjectedto 1% agarose gel electrophoresis.Forsequencing analysis
of exon 25, PCR fragments amplified using the two unique
oligonucleotide primers 59-cagggatccGTGGAAAACTTTCCG-
GACAGC-39 and 59-cgtgaattcACATGTTCTCATGTTCGGC-
TGC-39 (sequences from the cDNA are capitalized) were subcloned
into pEF-BOS [15]. More than ten different inserts were sequenced
for the indicated tissue. For detection of exons 11 and 12, PCR
analysis was performed using a forward primer 59-cagggatccGT-
CAAACCCTGGTCCAACATC-39 and a reverse primer 59-
gaactcgagtcaCCTGAACGAGGATGTGAGAAG-39 (sequences
from the cDNA are capitalized) [11].
Mice
Transgenic mice expressing Fhod3 that contained all the exons
except exon 25 under the control of the a-myosin heavy chain
promoter [16] were generated on a C57BL/6 background. Six
different founder lines showing different level of Fhod3 expression
in the heart were obtained without juvenile morbidity or mortality.
Among these lines, hemizygotes of line 4 showing minimal
expression of Fhod3 protein (Figure S2) were used for immuno-
fluorescent microscopic analysis, and hemizygotes of line 6
showing maximal expression of Fhod3 protein were used for
immuno-electron microscopic analysis. All mice were kept in a
specific pathogen-free animal facility at Kyushu University. All
procedures using mice were performed in strict accordance with
the guidelines for Proper Conduct of Animal Experiments (Science
Council of Japan). The experimental protocol was approved by
the Animal Care and Use Committee of Kyushu University
(Permit Number: A22-005-1). All efforts were made to minimize
the number of animals used and their suffering.
Human tissue preparation
Human heart tissue of a hypertrophic left ventricle was obtained
at the time of therapeutic surgery from a patient that suffered from
cardiac failure due to severe aortic stenosis. Cardiomyopathic
tissues of left ventricles were obtained at the time of therapeutic
surgery from two patients with idiopathic dilated cardiomyopathy
(DCM) and a patient with idiopathic hypertrophic cardiomyop-
athy (HCM). Myocardial tissues without apparent fibrosis were
subjected to immunofluorescence microscopy. Procedures using
human samples were conducted in accordance with the Declara-
tion of Helsinki and approved by the Kyushu University
Institutional Review Board for Clinical Research (Permit Number:
22-170). We obtained written informed consent from all the
participants. The dissected pieces of human heart tissue were
frozen in isopentane precooled with liquid nitrogen. Cryosections
(5 mm thick) were fixed in 3.7% formaldehyde and subjected to
immunofluorescence staining.
Mouse tissue preparation
C57BL/6 mice or transgenic mice, aged 3–4 weeks, were deeply
anesthetized with an intraperitoneal injection of pentobarbital
(50 mg/kg body weight). After exposure of the heart, 5 ml of PEM
buffer (1 mM EGTA, 1 mM MgCl2, and 100 mM PIPES,
pH 6.9) containing 20 mM KCl was administered from the left
ventricle, followed by the administration of 10 ml of 3.7%
formaldehyde in phosphate-buffered saline (PBS; 137 mM NaCl,
2.68 mM KCl, 8.1 mM Na2HPO4, and 1.47 mM KH2PO4,
pH 7.4). For facilitation of selective coronary perfusion, the
ascending aorta was clamped with a hemostat and the right
atrium was clipped with surgical scissors before the perfusion. For
preparation of the embryonic samples, timed pregnant mice were
sacrificed via cervical dislocation, and E15.5–16.5 embryos were
dissected from the uterus and anesthetized by hypothermia [17].
The hearts of embryos were exposed under a dissecting
microscope. After clamping of the ascending aorta and clipping
of the right atrium, 1 ml of PEM buffer containing 20 mM KCl
was administered from the left ventricle with a pulled capillary
tube, followed by perfusion of 3 ml of 3.7% formaldehyde. The
fixed hearts were removed from the deceased mice, cut into small
pieces, and immersed for 90 min at 4uC in the same fixative. The
tissues obtained were washed in PBS, subjected to osmotic
dehydration in 30% sucrose overnight at 4uC, and embedded in
Figure 4. Localization of Fhod3 in the heart of Fhod3 transgenic mice. (A) Sections of adult hearts from transgenic mice that specifically
express a high amount of the T(D/E)5XE-region-deficient Fhod3 protein in the heart were subjected to immunofluorescent double staining for Fhod3
(red) and a-actinin (green), followed by phalloidin staining. For Fhod3 staining, the anti-Fhod3-(C-20) (top panels), the anti-Fhod3-(650–802) (middle
panels), or the anti-Fhod3-(873–974) (bottom panels) polyclonal antibodies were used. Bar, 2 mm. (B) Sections of adult hearts from Fhod3 transgenic
mice were subjected to immunofluorescent double staining for Fhod3 (red) and myomesin (green). For Fhod3 staining, the anti-Fhod3-(650–802)
polyclonal antibodies were used. Bar, 2 mm. (C) Magnified image of single myofibril from immunostained sections of adult hearts of Fhod3 transgenic
mice. Sections were stained for a-actinin (green), phalloidin (blue), and Fhod3 or Tmod1 (red). For Fhod3 staining, the anti-Fhod3-(650–802) (top
panels), the anti-Fhod3-(873–974) (2nd panels), and the anti-Fhod3-(C-20) (3rd panels) polyclonal antibodies were used. Bar, 2 mm. (D) Fluorescence
intensity profiles in a line scan of sarcomeres. Line scan profiles of fluorescence intensities for the anti-a-actinin antibody (green) and the anti-Fhod3-
(C-20) or anti-Tmod antibodies (red) are generated from immunofluorescent images shown in C. (E) Distance between the Z-line and Fhod3 and that
between the Z-line and Tmod. The distance of the fluorescence peak of Fhod3 or Tmod from that of a-actinin are measured on immunofluorescent
images. Box-and-whisker plots indicate 25th percentile (bottom line), median (middle line), 75th percentile (top line), and nearest observations within
1.5 times the interquartile range (whiskers). *, P,0.001, Welch’s t test. (F) Magnified image of single myofibril from immunostained sections of adult
hearts of Fhod3 transgenic mice. Sections were stained for Fhod3 (red), Tmod1 (green), and phalloidin (blue). For Fhod3 staining, the anti-Fhod3-
(650–802) polyclonal antibodies were used. (G) Ultrastructural localization of Fhod3. Ultrathin cryosections of adult hearts from Fhod3 transgenic
mice were immunolabeled using the anti-Fhod3-(650–802) antibodies, and labeling was detected using gold-conjugated secondary antibodies.
doi:10.1371/journal.pone.0034765.g004
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cut into 5 mm sections using a cryostat (Thermo Scientific
HM550). The sections were air dried and stored at 280uC before
staining.
Primary culture of mouse embryonic cardiomyocytes
Primary cardiomyocytes were prepared from embryonic hearts
of C57BL/6 mice according to the method of Goshima [18] with
minor modifications. Briefly, hearts were isolated from E14.5–16.5
embryos, dissected and then digested with collagenase type II (300
units/ml, Worthington CLS2) for three successive periods of
10 min each at 37uC. Cells were preplated for 70 min into 90-mm
culture dishes in DMEM supplemented with 10% FCS to reduce
the number of non-myocytes. Unattached cells were plated and
cultured in DMEM with 10% FCS.
Immunofluorescence staining
Sections were washed with PBS containing 0.1% Triton X-100,
and blocked with a blocking buffer (PBS containing 3% bovine
serum albumin and 2% goat serum) for 2 h at room temperature.
Sections were labeled with primary antibodies diluted overnight at
4uC in the buffer containing 0.1% Triton X-100, washed in PBS
containing 0.1% Triton X-100, and then labeled for 1 h at 37uC
with a fluorescein-conjugated secondary antibody mixture in the
same buffer containing Alexa-647-phalloidine (Invitrogen) for F-
actin staining. In the case of Fhod3 staining in tissue sections,
F(ab’)2 fragments of anti-rabbit IgG was used. Cultured cardio-
myocytes were fixed in 3.7% formaldehyde and immunostained as
previously described [10]. Images shown in Figure 2C, Figure 3B,
Figure 3C, and Figure 4 (A–D) were taken with an LSM510
confocal scanning laser microscope (Carl Zeiss MicroImaging),
and images shown in Figure 2A, Figure 2B, Figure 3A, and
Figure 5A were with an Axiovert 200 microscope (Carl Zeiss
MicroImaging) coupled to an Axiocam HRm camera (Carl Zeiss
MicroImaging).
Immuno-electron microscopic analysis
Immuno-electron microscopy of ultrathin cryosections was
performed by the method of Tokuyasu [19] with minor
modifications. Briefly, the perfusion-fixed hearts of transgenic
mice expressing Fhod3 were cut into small pieces and immersed in
0.1 M sodium cacodylate containing 4% paraformaldehyde and
0.4% glutaraldehyde for 60 min at 4uC. After washing with PBS,
the tissues were cryoprotected in 2.3 M sucrose overnight at 4uC,
and frozen in liquid nitrogen. Ultrathin cryosections (100 nm
thick) were cut using a Leica EM UC7/FC7 cryo-ultarmicrotome
and sections were collected onto 100 mesh formvar/carbon-coated
nickel grids. After washing, grids were blocked in 3% BSA and 2%
goat serum, and incubated overnight with the anti-Fhod3-(650–
802) antibodies and subsequently incubated for 2 h with anti-
rabbit IgG antibody conjugated with 10-nm gold particle (EY lab).
Figure 5. Effect of the T(D/E)5XE region of Fhod3 on actin
assembly. (A) Effect of the Fhod3 T(D/E)5XE region encoded by exon
25 on in vivo actin assembly. HeLa cells were transfected with plasmids
encoding Fhod3-DN (wt) (amino acids 931–1,586) with or without the
T(D/E)5XE region in the FH2 domain; or plasmids encoding Fhod3-DN
(I1127A) with or without the T(D/E)5XE region. Cells were fixed and
visualized by GFP-fluorescence (green) or phalloidin staining (red). Scale
bar, 10 mm. (B) SDS-PAGE analysis of purified proteins used in an actin
polymerization assay. Purified proteins were subjected to 10% SDS-
PAGE and stained with Coomassie Brilliant Blue. Positions for marker
proteins are indicated in kDa. (C) Effect of the T(D/E)5XE region of Fhod3
on in vitro actin assembly. G-actin (10% pyrene-labeled) at 2 mM was
incubated with 50 nM Fhod3-T(D/E)5XE(+)-DN (wt), Fhod3-T(D/E)5XE(+)-
DN (I1127A), Fhod3-T(D/E)5XE(2)-DN (wt), or mDia1-FH1FH2 (amino
acids 549–1,175) in the presence of 2 mM profilin I.
doi:10.1371/journal.pone.0034765.g005
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embedded in a mixture containing 2% polyvinyl alcohol and 0.2%
uranyl acetate. Sections were analyzed on a Tecnai-20 transmis-
sion electron microscope (FEI Corp.), and images were collected
with an Eagle 2k HR digital camera (FEI Corp.). The primary
antibodies-specific labeling was confirmed by control experiments
in which primary antibodies are omitted.
In vivo actin assembly assay
HeLa cells were transfected using Lipofectamine (Invitrogen)
with a plasmid for Fhod3-DN (wt) (amino acids 931–1,586) with or
without the T(D/E)5XE region or one for Fhod3-DN (I1127A)
with or without the T(D/E)5XE region, and cultured for 3 h. After
the addition of DMEM containing 10% fetal calf serum (FCS),
cells were cultured for another 13 h. After washing with PBS, cells
were fixed for 15 min in 3.7% formaldehyde, permeabilized for
4 min with 0.1% Triton X-100 in PBS, and blocked for 60 min
with PBS containing 3% BSA. For F-actin staining, Texas Red-X
phalloidin (Invitrogen) was used. Images were taken with an
Axiovert 200 microscope (Carl Zeiss MicroImaging) coupled to an
Axiocam HRm camera (Carl Zeiss MicroImaging).
In vitro actin polymerization assay
Fhod3 and mDia1 proteins for an actin polymerization assay
were prepared as described previously [10]. Briefly, FreeStyle
HEK-293F cells (Invitrogen) were transfected with an expression
vector encoding the cDNA for Fhod3 or mDia1. The transfected
cells were broken with the lysis buffer, and the lysate was
precipitated with an anti-FLAG antibody (M2)-conjugated agarose
(Sigma-Aldrich). Proteins eluted with FLAG-peptide (200 mg/ml)
in X buffer (2 mM MgCl2, 100 mM KCl, 0.1 mM CaCl2,5m M
EGTA, 1 mM DTT, and 10 mM Hepes, pH 7.9) were used for
an actin polymerization assay as described below. Human profilin
I were expressed in E.coli as a glutathione S-transferase (GST)
fusion protein, purified by glutathione-Sepharose 4B (GE
Healthcare), and cleaved with PreScission protease (GE Health-
care). Pyrene-actin polymerization assays were performed in X
buffer as described previously [10]. Briefly, G-actin (10% pyrene-
labeled) was prepared in G buffer (0.2 mM CaCl2, 0.2 mM ATP,
0.2 mM DTT, and 5 mM Tris-HCl, pH 8.0). Polymerization
reactions were performed in 100 ml of X buffer containing 2 mM
actin (10% pyrene-labeled), 2 mM profilin I, and 50 nM Fhod3-
DN or mDia1-FH1FH2 (amino acids 549–1,175). All reaction
components except the actin were mixed in X buffer, and the
reaction was started by the addition of actin. Fluorescence changes
(excitation wavelength of 365 nm; emission wavelength of
407 nm) were measured using the multilabel plate reader EnSpire
(Perkin Elmer).
Immunoblot analysis
Immunoblot analysis was performed as previously described
[10,11]. Briefly, hearts of mice were homogenized and sonicated at
4uC in a lysis buffer (10% glycerol, 135 mM NaCl, 5 mM EDTA,
and 20 mM Hepes, pH 7.4) containing Protease inhibitor cocktail
(Sigma-Aldrich). The lysates were applied to SDS-PAGE and
transferred to a polyvinylidene difluoride membrane (Millipore).
The membrane was probed with the anti-Fhod3-C20 antibodies,
followed by development using ECL-plus (GE Healthcare) for
visualization of the antibodies.
Supporting Information
Figure S1 Localization of Fhod3 in the adult heart.
Sections of adult mouse hearts were subjected to immunofluores-
cent double staining with the untreated anti-Fhod3-(C-20)
antibodies (red) and the anti-a-actinin monoclonal antibody
(green) followed by phalloidin staining. Bar, 2 mm.
(PDF)
Figure S2 Cardiac expression of Fhod3 in the transgenic
mice expressing Fhod3. Cardiac tissue lysates (5 mg of protein)
from transgenic mice (Tg) aged 3 weeks or non-transgenic mice
(Non-Tg) aged 3 weeks were analyzed by immunoblot with the
anti-Fhod3-(C-20) antibodies.
(TIF)
Figure S3 Characterization of the affinity-purified poly-
clonal antibodies against Fhod3. Lysates of cardiac tissues
(5 mg of protein) from Fhod3 knockout mouse embryos at E10.5 or
heterozygous Fhod3
+/2 mouse embryos at E10.5 were analyzed by
immunoblot with the anti-Fhod3-(650–802) and anti-GAPDH
antibodies.
(PDF)
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